| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
LMAT
Lemaitre Vascular
|
May 06, 2026 | BUY |
Strong Buy
-0.6% avg upside
15 analysts
|
$132.00
28.31% Upside
|
-10.2% |
|
VREX
Varex Imaging
|
Jan 14, 2026 | BUY |
Strong Buy
+90.2% avg upside
9 analysts
|
$22.00
107.32% Upside
|
-21.9% |
|
MMSI
Merit Medical Systems
|
Jan 09, 2026 | BUY |
Strong Buy
+28.1% avg upside
15 analysts
|
$122.00
71.55% Upside
|
-27.6% |
|
RDNT
Radnet
|
Sep 16, 2025 | BUY |
Strong Buy
+16.7% avg upside
10 analysts
|
$92.00
33.73% Upside
|
-7.5% |
|
STAA
Staar Surgical
|
Aug 05, 2025 | HOLD |
Hold
+19.7% avg upside
16 analysts
|
$28.00
0.67% Upside
|
+2.9% |
|
ANIK
Anika Therapeutics
|
May 28, 2025 | BUY |
Strong Buy
+28.1% avg upside
4 analysts
|
$24.00
56.20% Upside
|
+34.0% |
|
SGC
Superior Group of Companies
|
May 09, 2025 | HOLD |
Strong Buy
+32.8% avg upside
6 analysts
|
$20.00
53.44% Upside
|
+17.7% |
|
IL:KMDA
Kamada
|
May 08, 2025 | HOLD |
Strong Buy
+69.4% avg upside
7 analysts
|
$3902.66
73.49% Upside
|
· |
|
INFU
InfuSystem Holdings
|
Mar 18, 2025 | BUY |
Strong Buy
+42.2% avg upside
7 analysts
|
$15.00
47.70% Upside
|
+65.9% |
|
CODX
Co-Diagnostics
|
Aug 12, 2022 | HOLD |
Buy
+541.6% avg upside
5 analysts
|
$5.00
67.19% Upside
|
-74.1% |
|
ITGR
Integer Holdings
|
May 08, 2020 | BUY |
Buy
+1.3% avg upside
15 analysts
|
$108.00
13.53% Upside
|
+24.3% |
|
HAE
Haemonetics
|
Aug 15, 2016 | HOLD |
Buy
-10.4% avg upside
17 analysts
|
$39.00
48.11% Downside
|
+19.2% |
|
GADS
Gadsden Prop
|
Jul 22, 2013 | BUY |
Buy
+8999900.1% avg upside
5 analysts
|
— | · |
|
TFX
Teleflex
|
Apr 01, 2013 | HOLD |
Buy
+35.0% avg upside
19 analysts
|
— | +29.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.